Larry Steven Boulet Net Worth

The estimated Net Worth of Larry Steven Boulet is at least $247 millier dollars as of 17 August 2012. Larry Boulet owns over 11,500 units of Basis Global Technologies Inc stock worth over $246,600 and over the last 17 years Larry sold BASI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Larry Boulet BASI stock SEC Form 4 insiders trading

Larry has made over 2 trades of the Basis Global Technologies Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Larry bought 11,500 units of BASI stock worth $14,490 on 17 August 2012.

The largest trade Larry's ever made was buying 11,500 units of Basis Global Technologies Inc stock on 17 August 2012 worth over $14,490. On average, Larry trades about 3,750 units every 476 days since 2007. As of 17 August 2012 Larry still owns at least 15,000 units of Basis Global Technologies Inc stock.

You can see the complete history of Larry Boulet stock trades at the bottom of the page.

What's Larry Boulet's mailing address?

Larry's mailing address filed with the SEC is 9075 PICKWICK DRIVE, , INDIANAPOLIS, IN, 46260.

Insiders trading at Basis Global Technologies Inc

Over the last 21 years, insiders at Basis Global Technologies Inc have traded over $266,443 worth of Basis Global Technologies Inc stock and bought 540,162 units worth $1,698,287 . The most active insiders traders include Jacqueline M Lemke, Robert Jr. Leasure et William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of $128,544. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth $88,500.

What does Basis Global Technologies Inc do?

Complete history of Larry Boulet stock trades at Basis Global Technologies Inc

Basis Global Technologies Inc executives and stock owners

Basis Global Technologies Inc executives and other stock owners filed with the SEC include:

• Wendy Perrow,
  Independent Director
• R. Matthew Neff,
  Independent Director
• Richard Johnson,
  Independent Director
• Joseph Flynn,
  Chief Commercial Officer
• John Sagartz,
  Chief Strategy Officer, Director
• Connie Dougherty,
  Vice President - Business Development
• I.M. Grossi,
  Vice President - Toxicology
• Philip Downing,
  Vice President - Preclinical Services
• Andrew Alexander,
  Vice President - Pharmacology and Toxicology Operations
• Michael Baim,
  Vice President - Bioanalytical Operations
• Beth Taylor,
  Chief Financial Officer, Vice President - Finance
• Robert Leasure,
  President, Chief Executive Officer, Director
• Gregory Davis,
  Interim Chairman of the Board
• Jill Blumhoff,
  VP, Finance & CFO
• John P Devine,
  VP--Toxicology
• James Sevall Bourdage,
  VP, Bioanalytical Services
• Jacqueline M Lemke,
  CFO & Vice President--Finance
• Jeffrey Potrzebowski,
  VP, Finance & CFO
• John Gregory Beattie,
  Chief Operating Officer
• Peterkissinger Candice B Ki...,
  
• Daniel Thomas Oakley,
  Chief Operating Officer
• Kimberly L Sagartz,
  10% owner
• Chrysalis, Llc Sw,
  10% owner
• Lori Payne,
  VP Bioanalytical Services
• Larry Steven Boulet,
  Director
• David W Crabb,
  Director
• John B. Landis,
  Director
• David L Omachinski,
  Director
• Anthony S Chilton,
  COO, Scientific Studies
• A. Charlene Sullivan,
  Director
• Alberto F Jr Hidalgo,
  VP, Bus. Development & Mrkting
• Leslie B Daniels,
  Director
• Kathleen Hodges,
  Vice President of Quality
• Lina L Reeves Kerner,
  V.P. - Human Resources
• Richard M Shepperd,
  President & Chief Exec. Off.
• Ronald E Shoup,
  Chief Operating Officer
• Craig S Bruntlett,
  Sr. V.P. International Sales
• Jon Brewer,
  VP Sales/Marketing
• William E Baitinger,
  Director
• Candice B Kissinger,
  Vice President
• Margaret B Mcclure,
  Dir, Pharmaceutical Lab. Div.
• Michael R Cox,
  V.P. Finance, CFO
• Emilio Cordova,
  V.P. of Business Development
• Edward Chait,
  Executive Vice President
• Gerry Henningsen,
  Director BAS Evansville
• Donnie A Evans,
  Vice President Engineering
• Garyl W Doster,
  Director
• Michael P Silvon,
  Vice President
• Michael S Noone,
  Dir. of Clinical Affairs, Balt
• William Sawyers,
  Laboratory Director
• William D Pitchford,
  Chief HR Officer